Japanese scientists are pushing an entry blocker, AK602, into human trials. The makers of Sifuvirtide, a Chinese fusion inhibitor, say it outperforms Fuzeon in the lab.  And in Britain, TAT inhibitors (TAT’s an HIV protein), whose toxicity and lack of oomph have stalled them in the U.S. pipeline, now rise from the near-dead to enter trials as a Swedish company’s BI-201. Passport, please.